These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 17988241)

  • 1. VMAT2 and dopamine neuron loss in a primate model of Parkinson's disease.
    Chen MK; Kuwabara H; Zhou Y; Adams RJ; Brasić JR; McGlothan JL; Verina T; Burton NC; Alexander M; Kumar A; Wong DF; Guilarte TR
    J Neurochem; 2008 Apr; 105(1):78-90. PubMed ID: 17988241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is Parkinson's disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum.
    Pifl C; Rajput A; Reither H; Blesa J; Cavada C; Obeso JA; Rajput AH; Hornykiewicz O
    J Neurosci; 2014 Jun; 34(24):8210-8. PubMed ID: 24920625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo measures of nigrostriatal neuronal response to unilateral MPTP treatment.
    Tian L; Karimi M; Brown CA; Loftin SK; Perlmutter JS
    Brain Res; 2014 Jul; 1571():49-60. PubMed ID: 24845719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
    Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
    Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ginkgo biloba extract (EGb 761) modulates the expression of dopamine-related genes in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
    Rojas P; Ruiz-Sánchez E; Rojas C; Ogren SO
    Neuroscience; 2012 Oct; 223():246-57. PubMed ID: 22885234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The nigrostriatal system in the presymptomatic and symptomatic stages in the MPTP monkey model: a PET, histological and biochemical study.
    Blesa J; Pifl C; Sánchez-González MA; Juri C; García-Cabezas MA; Adánez R; Iglesias E; Collantes M; Peñuelas I; Sánchez-Hernández JJ; Rodríguez-Oroz MC; Avendaño C; Hornykiewicz O; Cavada C; Obeso JA
    Neurobiol Dis; 2012 Oct; 48(1):79-91. PubMed ID: 22677034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential loss of presynaptic dopaminergic markers in Parkinsonian monkeys.
    Stephenson DT; Childs MA; Li Q; Carvajal-Gonzalez S; Opsahl A; Tengowski M; Meglasson MD; Merchant K; Emborg ME
    Cell Transplant; 2007; 16(3):229-44. PubMed ID: 17503735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intervention with exercise restores motor deficits but not nigrostriatal loss in a progressive MPTP mouse model of Parkinson's disease.
    Sconce MD; Churchill MJ; Greene RE; Meshul CK
    Neuroscience; 2015 Jul; 299():156-74. PubMed ID: 25943481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroPET imaging of vesicular monoamine transporter 2 revealed the potentiation of (+)-dihydrotetrabenazine on MPTP-induced degeneration of dopaminergic neurons.
    Xu Y; Tang J; Liu C; Zhao C; Cao S; Yu H; Chen Z; Xie M
    Nucl Med Biol; 2021; 96-97():9-18. PubMed ID: 33647803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oestrogens prevent loss of dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) in substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice.
    Jourdain S; Morissette M; Morin N; Di Paolo T
    J Neuroendocrinol; 2005 Aug; 17(8):509-17. PubMed ID: 16011487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased vesicular monoamine transporter type 2 availability in the striatum following chronic cocaine self-administration in nonhuman primates.
    Narendran R; Jedema HP; Lopresti BJ; Mason NS; Himes ML; Bradberry CW
    Biol Psychiatry; 2015 Mar; 77(5):488-92. PubMed ID: 25062684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No differential regulation of dopamine transporter (DAT) and vesicular monoamine transporter 2 (VMAT2) binding in a primate model of Parkinson disease.
    Tian L; Karimi M; Loftin SK; Brown CA; Xia H; Xu J; Mach RH; Perlmutter JS
    PLoS One; 2012; 7(2):e31439. PubMed ID: 22359591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progressive loss of striatal dopamine terminals in MPTP-induced acute parkinsonism in cynomolgus monkeys using vesicular monoamine transporter type 2 PET imaging ([(18)F]AV-133).
    Liu Y; Yue F; Tang R; Tao G; Pan X; Zhu L; Kung HF; Chan P
    Neurosci Bull; 2014 Jun; 30(3):409-16. PubMed ID: 24061965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of dopaminergic and glutamatergic brain function: PET studies on parkinsonian rats.
    Pellegrino D; Cicchetti F; Wang X; Zhu A; Yu M; Saint-Pierre M; Brownell AL
    J Nucl Med; 2007 Jul; 48(7):1147-53. PubMed ID: 17574972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen receptors and gonadal steroids in vulnerability and protection of dopamine neurons in a mouse model of Parkinson's disease.
    Al-Sweidi S; Morissette M; Bourque M; Di Paolo T
    Neuropharmacology; 2011 Sep; 61(4):583-91. PubMed ID: 21586296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice.
    Kilbourn MR; Kuszpit K; Sherman P
    Synapse; 2000 Mar; 35(4):250-5. PubMed ID: 10657034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vesicular Monoamine Transporter 2 (VMAT2) Level Regulates MPTP Vulnerability and Clearance of Excess Dopamine in Mouse Striatal Terminals.
    Lohr KM; Chen M; Hoffman CA; McDaniel MJ; Stout KA; Dunn AR; Wang M; Bernstein AI; Miller GW
    Toxicol Sci; 2016 Sep; 153(1):79-88. PubMed ID: 27287315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.
    Longo F; Mercatelli D; Novello S; Arcuri L; Brugnoli A; Vincenzi F; Russo I; Berti G; Mabrouk OS; Kennedy RT; Shimshek DR; Varani K; Bubacco L; Greggio E; Morari M
    Acta Neuropathol Commun; 2017 Mar; 5(1):22. PubMed ID: 28292328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo quantification of glial activation in minipigs overexpressing human α-synuclein.
    Lillethorup TP; Glud AN; Landeck N; Alstrup AKO; Jakobsen S; Vang K; Doudet DJ; Brooks DJ; Kirik D; Hinz R; Sørensen JC; Landau AM
    Synapse; 2018 Dec; 72(12):e22060. PubMed ID: 30009467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: Is VMAT2 a stable dopamine neuron biomarker?
    Boileau I; Rusjan P; Houle S; Wilkins D; Tong J; Selby P; Guttman M; Saint-Cyr JA; Wilson AA; Kish SJ
    J Neurosci; 2008 Sep; 28(39):9850-6. PubMed ID: 18815269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.